Kornimate/medical-research-clean huggingface dataset:
results of the treatment of patients with elbow osteoarthritis

Conditions: Elbow Osteoarthritis

Summary: the study is a prospective case controlled clinical trial. the purpose of the study is to investigate the effect of elbow arthroscopy in the treatment for osteoarthritis of the elbow when compared to conservative treatment.

patients will be recruited at departments of hand surgery and orthopedic surgery outpatient clinics. the control group will be patients to whom the conservative treatment continues. patients who meet the inclusion criteria will be asked to participate and sign the informed consent. therefore the investigators have two treatment groups: group 1 who receives an elbow joint debridement arthroscopically without physiotherapy and group 2 who receives only conservative treatment with physiotherapy.

Eligibility criteria:
inclusion criteria: * symptomatic post-traumatic or primary osteoarthritis - mechanical locking and/or decreased range of motion ( \>30°) * radiographic evidence of at least mild primary or post-traumatic osteoarthritis according to broberg - morrey classification symptoms lasting at least 6 months * patients willingness to participate the study * all patients 18-80 ages exclusion criteria: * patients with previous severe soft tissue trauma at elbow region ( crush, burns etc - the elbow joint problems are not joint specific) * patients with crystal arthropathy or inflammatory arthritis * patient refuses to participate the study * patients with dementia or are institutionalized * patients with severe substance addiction * patient does not understand written and spoken guidance

Keywords: elbow arthroscopy dash elbow locking elbow osteoarthritis
adrenaline solution irrigation and bleeding during sinus surgery

Conditions: Chronic Rhinosinusitis (Diagnosis)

Summary: intranasal irrigation with normal saline is routinely used in sinus surgery to clean the tip of the nasal endoscope and clear the surgical field from blood. the purpose of this study is to evaluate the difference in the surgical visualization, surgeon satisfaction and total blood loss when intraoperative irrigation was performed with a solution of normal saline with adrenaline as compared to irrigation with normal saline alone in fess.

functional endoscopic sinus surgery (fess) is a common, effective and minimally invasive surgical procedure indicated mainly to treat medically resistant chronic rhinosinusitis with or without nasal polyposis. the surgery is often performed under general anesthesia and proceeds in anatomically based surgical landmarks steps to facilitate drainage and ventilation of the paranasal sinuses. as any other endoscopic and laparoscopic procedures the operation requires dry surgical field to ensure accurate identification and visualization of structures and smooth surgical dissection progression. intranasal bleeding during fess will increase time of surgery and perioperative complications. also it could affect healing process, increase adhesion formation and lengthening recovery period . different methods and maneuvers have been described in the literature to reduce intra-operative bleeding during sinus surgery. these include: elevation of the patient's head, the use of bipolar cautery and powered instruments; premedication with beta blockers; a controlled hypotensive anesthesia technique; total intravenous anesthesia, topical hemostatic biomaterials and local application of vasoconstrictors. adrenaline is one of the most commonly used topical vasoconstrective agent. because systemic absorption of infiltrated adrenaline can give rise to a sudden increase in blood levels of catecholamine compared to topical instillation and thus various life-threatening complications, such as : cardiac arrhythmia, cardiac arrest, cardiomyopathy, pulmonary edema, and central retinal artery occlusion; many surgeons prefer to use instillation of adrenaline over infiltration in fess

Eligibility criteria:
inclusion criteria: * patients with american society of anesthesiologist (asa) classification \<2 * patients with chronic with or without nasal polyposis refractory to medical treatment exclusion criteria: * patients with a history of of bleeding diathesis * patients with severe ischemic heart disease , pulmonary and renal disease * patients with tumours or vascular anomalies * patients with cystic fibrosis, allergic fungal sinusitis and granulomatous disorders * patients who are unable to speak, read and write english

Keywords: sinusitis nasal polyp endoscopic sinus surgery adrenaline
ect in ultra-resistant schizophrenia

Conditions: Schizophrenia; Electroconvulsive Therapy

Summary: the effects of the ect in schizophrenia ultra-resistant were studied in short times (4-6 months in most studies with follow-up). the literature identified a high relapse rate of 32% in the weeks to months after ect discontinuation. the use of the ect in the prevention of the relapse is partially known. in an empirical way, experts recommend protocols of prevention of the relapse going from 6 to 12 months. nevertheless, the profit of a long cure (12 months) compared with a short cure (6 months) was never determined. therefore, the investigators decided to lead a prospective randomized controlled study in order to compare the response rates between the two strategies of clozapine and ect combinations applied to urs patients. the treatment consisted either in a short therapy of six months or a longer course of therapy of twelve months. to the investigators' knowledge, it is the first study which compares two ect strategies (both the short duration and the longer one) for the treatment of urs patients.


Eligibility criteria:
inclusion criteria: * patients with urs: patients who continue to experience persistent positive psychotic symptoms: item score of 4 (moderate) on at least two of four positive symptoms on the bprs (grandiosity, suspiciousness, hallucinations and unusual thoughts), current presence of at least moderately severe illness on the total bprs-18 (45) and a score of 4 (moderate) on the cgi-s, despite a period of clozapine therapy of at least 6 weeks with a plasma concentration of 350 ng/ml and at least two unsuccessful previous treatment trials with conventional or atypical antipsychotic drugs from two distinct families at a dose 600 mg of chlorpromazine equivalents. * age: from 18 to 55 * patients with stable treatments for at least 8 weeks (antipsychotics, mood stabilizers and antidepressants). * participants who gave their informed, written consents and agreement of their guardian for the patients under guardianship * patients deprived of liberty if they gave their informed, written consents exclusion criteria: * current affective episode according to dsm-5 criteria; * ect within (the last) 6 months; * unstable epilepsy ; severe neurological or systemic disorder that could significantly affect cognition, behavior, or mental status (other than late dyskinesia or neuroleptic-induced parkinsonism); * severe substance use disorders (other than nicotine or caffeine) according to dsm-5 criteria. * concomitant use of antiepileptics and benzodiazepines apart from lamotrigine * women of childbearing age with no adequate contraception, pregnant or lactating women; * patients having contraindications to etomidate or any of its excipients; * patients having contraindications to neuromuscular blocking agents; * patients participating or having participated in an interventional clinical trial within 30 days prior to the inclusion visit;
prospective collection of female specimens for testing with gen-probe aptima (registered trademark) assays

Conditions: Chlamydia Infections; Gonorrhea; Trichomonas Infections

Summary: the objective of this study is to obtain female first-catch urine, vaginal, cervical and endocervical swabs for testing with multiple aptima assays on the gen-probe panther® and tigris® systems.


Eligibility criteria:
inclusion criteria: * the subject is at least 16 years of age at the time of enrollment and is currently sexually active (has had penile/vaginal intercourse within the past 12 months) * the subject and/or legally authorized representative is willing to undergo the informed consent process prior to study participation (a minor will need the documented consent of his/her parent or legal guardian, unless the site has an institutional review board \[irb\]-approved waiver for parental consent for minors) in addition, the subject must meet at least one of the following criteria: * the subject reports symptoms consistent with a suspected sexually transmissible infection (sti) such as abnormal discharge, genital itching, pain/discomfort during sexual intercourse or urination, and/or lower abdominal discomfort * subject is asymptomatic and known to be partners with, or a contact of, a person with a confirmed or suspected sti(s) * subject is asymptomatic and undergoing screening evaluation for possible stis * subject is asymptomatic and undergoing a routine examination with a pelvic examination exclusion criteria: * the subject took antibiotic medications within the last 21 days * subject already participated in this study * subject has a history of illness that the principal investigator (pi) or designee considers could interfere with or affect the conduct, results, and/or completion of the clinical trial * subject has a history of illness that the pi or designee considers could create an unacceptable risk to the subject if enrolled
prospective study assessing the validity of y-pas (yale preoperative anxiety scale) to predict patients undergoing magnetic resonance imaging without the use of sedation/general anesthesia

Conditions: Magnetic Resonance Imaging

Summary: the mypas (modified yale preoperative anxiety scale) is a quick, easy, validated and "gold standard" assessment tool to measure pediatric anxiety in the perioperative period. therefore the objective of the current prospective study is examine if the my-pas is an effective screening tool to differentiate patients who would succeed versus fail for mri without sedation/anesthesia.


Eligibility criteria:
inclusion criteria: * all patients and parents who are willing to participate in the simulated practice mri on the day of or prior to their scheduled mri. exclusion criteria: * patients/parents who refuse to go through the practice mri sessions.
hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.

Conditions: Hemoperfusion; Multiorgan Failure; Sepsis

Summary: low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.


Eligibility criteria:
inclusion criteria: * patients with a sepsis diagnosis, according to the diagnostic criteria of the international sepsis-3 consensus conference, and without response to the treatment of septic shock who meet the following conditions: * sepsis of abdominal origin with controlled infectious focus. * noradrenaline dose\> 0.5 µg / kg / min to maintain adequate organ perfusion after optimization of fluid therapy. * dysfunction of two or more organs with sofa ≥ 9 (5). * blood lactate ≥ 2 mmol / l. * procalcitonin (pct)\> 10 ng / ml. * crp\> 100 mg / l. * il-6\> 2000 pg / ml. exclusion criteria: * age under 18 years or over 80 years. * pregnancy or breastfeeding. * terminally ill patients or with a life expectancy of less than 48 hours. * thrombocytopenia \<60,000 / mm3. * pancytopenia. * severe coagulopathy with high risk of bleeding. * inclusion in another research protocol. * in case of re-entry during the study period, only the first admission will be included. * use of another haemoperfusion device.
correlation of ultrasound based measurements of liver stiffness and steatosis with mri

Conditions: Liver Steatoses; Liver Cirrhosis

Summary: the investigators will assess the ability of ultrasound (us) to measure liver stiffness (cirrhosis) and liver fat content (steatosis).

non-invasive monitoring of liver fibrosis using magnetic resonance imaging (mri) can help determine which patients will most benefit from interventional therapies to help reverse the condition. similarly, quantitative assessment of liver fat content using mri can assist physicians in identifying patients at risk for hepatic steatohepatitis. due to the widespread dissemination of us machines and their relative lower cost compared to other imaging modalities, e.g. mri, the ability of us to assess these parameters widens diagnostic availability. patients who have undergone an mri exam to assess liver stiffness (cirrhosis) and/or liver fat content (steatosis) will be asked to undergo an us exam to assess the same parameters. the cirrhosis and steatosis measurements obtained from both exams will be compared. if us-based measurements of liver stiffness and/or liver fat content are shown to be reproducible and accurate when compared to mri values (will be used as the gold standard), us may become the first-line diagnostic test for these liver conditions.

Eligibility criteria:
inclusion criteria: 1. participants who have a clinical indication for a standard of care mri exam that included assessment of the liver 2. participant is at least 18 years of age exclusion criteria: 1. participants unable to take part in the decision making process on whether to consent to the trial 2. patients with previous chemoembolization or other focal liver therapies to the liver (\* note: for liver transplant patients, this criterion is only applicable to the transplanted liver)
cognitive-driven adl impairment as a predictor for pdd

Conditions: Parkinson Disease

Summary: mild cognitive impairment in parkinson's disease (pd-mci) is the highest risk factor for parkinson's disease dementia (pdd). the core feature for differentiating pdd from pd-mci is the loss of the ability to perform activities of daily living (adl). as parkinson's disease (pd) is primarily a movement disorder, the distinction between motor and cognitive contributions to adl in pd is an obvious challenge, which the investigators aimed to explore in this study. the goal of the study is to evaluate whether pd-mci patients with more pronounced, cognitive-driven adl impairment are at higher risk for cognitive worsening and pdd. a longitudinal follow-up assessment of 262 non-demented pd patients will be conducted over the next two years, with a comprehensive clinical assessment as well as biomarker sampling (cerebrospinal fluid and blood markers). primary longitudinal outcome will be conversion to pdd and pd-mci. conversion rates of patients with and without additional mild cognitive-driven adl impairment at baseline will be compared. novel scores of the pfeffer functional activities questionnaire (faq) are used to assess instrumental adl, differentiating between cognitive- and motor-driven adl impairment in pd-mci.


Eligibility criteria:
inclusion criteria: * participation in the baseline assessment * ability to communicate well with the investigator, to understand and comply with the requirements of the study. * provide written informed consent to participate in the study and understand their right to withdraw consent at any time without prejudice to future medical care. exclusion criteria: * any disability that may prevent the subject from completing the informed consent form or other study requirements. * other neurodegenerative disease which renders the subject unable to communicate well with the investigator or to understand and comply with the requirements of the study. * participation in any clinical investigation of a new investigational compound or therapy within 4 weeks prior to baseline visit, and for any other limitation of participation based on local regulations. * alcohol, medication or drug dependency or abuse (except for nicotine). * history of brain disease other than pd, e.g. head trauma, stroke, encephalitis, etc.

Keywords: activity of daily living function cognitive impairment parkinson's disease dementia
a study of laquinimod eye-drops in healthy participants

Conditions: Eye Diseases

Summary: this is a phase 1 randomized, double-masked, placebo-controlled study performed with healthy participants to assess the safety and tolerability of laquinimod eye-drops.

laquinimod administered as an oral capsule formulation has previously been studied in neurodegenerative and autoimmune diseases. the clinical side effect profile of orally administered laquinimod is well-characterized based on this previous experience. this trial will establish a safe and tolerated dose of laquinimod when administered as an eye-drop formulation following single ascending dose (sad) and multiple ascending dose (mad) administrations. there are four planned groups in the sad-part of the study which will enroll 28 participants, if all dose levels are explored. the subsequent mad-part of the study will enroll another 28 participants.

Eligibility criteria:
main inclusion criteria: * in good health according to medical history, physical examination, vital signs, ecg and clinical chemistry, urinary and hematological laboratory tests main exclusion criteria: * unable or unwilling to use eye-drops * current usage of contact lenses * history of eye surgery * sign or symptom of active eye disease * history of an eye disease or other condition that could interfere with eye examinations in the study, or with ocular absorption of the investigational product * history of inflammatory ocular disease * history of cardiovascular or pulmonary disorder * family history of known or suspected hereditary cardiovascular disease * autoimmune disease or known family history of autoimmune disease * any other condition that would contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures
exploring the benefit of peripheral nerve stimulation in treating pain from chemo-induced peripheral neuropathy: a longitudinal single center feasibility study

Conditions: Peripheral Nerve Stimulation; Chemotherapy-induced Peripheral Neuropathy

Summary: to learn if peripheral nerve stimulation (pns) can help to improve pain in participants with cipn.

primary objective: to assess pain intensity (nrs) scores in chemotherapy induced peripheral neuropathy (cipn) participants before and after use of peripheral nerve stimulation (pns). secondary objectives: to assess changes in quantitative sensory testing (qst), gait testing, and skin punch biopsy to compare the integrity of meissner's corpuscles (mc), pain disability using the oswestry disability index (odi), pain interference using the brief pain inventory (bpi), and patient global impression of change (pgic) in cipn patients before and after use of pns.

Eligibility criteria:
inclusion criteria: * participants diagnosed with chronic (≥90 days duration) cipn (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at pain management center at md anderson cancer center * participants reports baseline pain ≥ 4 (0-10 scale, nrs) * participants between ages 18-85 years old * participants who have completed chemotherapy within the previous year at the time of enrollment exclusion criteria: * participants with cognitive dysfunction * participants with recent history (\<6 months) of drug or alcohol abuse * participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * participants with allergies to local anesthesia, steroids, or adhesives * participants with conditions that conflict with the sprint pns system indications for use, including contraindications and warnings.
hcv genotype 1a shows a better virological response to antiviral therapy than hcv genotype 1b

Conditions: Chronic Hepatitis C

Summary: sustained virological response (svr) to antiviral therapy in patients with chronic hepatitis c genotype 1 according to subtype (1a vs.1b) has not been extensively investigated. this observational study was carried out on a large group of "naïve" hcv patients to evaluate difference, if any, between hcv genotype 1 subtype 1a and 1b on the response to treatment with peginterferon (peg-ifn) plus ribavirin.

despite the challenging perspective of the new antiviral drugs directly acting on hepatitis c viral replication such as protease and polymerase inhibitors, nowadays the standard treatment in genotype 1-chronic hepatitis c (chc) is the combination of peghylated interferon (peg-ifn) and ribavirin for 48 weeks. it has been extensively shown that patients infected with hcv genotype 1 have a lower rate of viral response than those infected with genotype 2 and 3. in large randomized multinational trials, sustained virological response (svr) of around 50% has been obtained with peginterferon α2a plus ribavirin in the more difficult to treat subgroup of patients infected with hcv genotype 1. furthermore, advanced fibrosis is a predictive factor of non response to antiviral treatment in genotype 1 virus \[5-7\]. very few studies have evaluated svr difference, if any, between subtypes 1a and 1b. we have carried out an observational study on a large cohort of hcv "naïve" patients to evaluate the influence of hcv subtypes 1 on the response to treatment with peg-inf plus ribavirin.

Eligibility criteria:
inclusion criteria: * eligible subjects were naïve infected with hcv genotype 1 virus meeting the internationally recognised criteria for treatment (elevation of aminotransferases, inflammation and or fibrosis at liver biopsy). exclusion criteria: * infection with human immunodeficiency virus (hiv) or hepatitis b virus (hbv) * alcohol intake greater than 20 gr daily * the presence of active drug abuse, chronic systemic disease, psychiatric disorders, autoimmune disease, pregnancy or lactation.

Keywords: hcv infection genotype 1a genotype 1 b
clinical research study to assess the efficacy of two brushing regimens in the reduction of established dental plaque and gingivitis.

Conditions: Gingivitis; Plaque

Summary: qualified subjects will be enrolled and randomized to one of the two study groups based on their initial plaque and gingivitis scores. subjects will be instructed to use the products according to the instructions provided. subjects will return to the dental office for evaluation after 1-, 3-, 6-, and 12-weeks of unsupervised product use at home. all subjects will be followed for adverse events throughout the study


Eligibility criteria:
inclusion criteria: * signed informed consent form. * male and female subjects aged 18-70 years, inclusive. * availability for the twelve-week duration of the clinical research study. * good general health based on the opinion of the study investigator * minimum of 20 permanent natural teeth (excluding third molars). * initial gingivitis index of at least 1.0 as determined by the use of the loe and silness gingival index. * initial plaque index of at least 1.5 as determined by the use of the quigley and hein plaque index (turesky modification) exclusion criteria: * presence of orthodontic appliances. * presence of partial removable dentures. * tumor(s) of the soft or hard tissues of the oral cavity. * moderate and/or advanced periodontal disease, rampant caries, or any condition that the dental examiner considers exclusionary from the study. * five or more carious lesions requiring immediate restorative treatment. * antibiotic use any time during the one-month period prior to entry into the study. * participation in any other clinical study or test panel within the one month prior to entry into the study. * dental prophylaxis during the past two weeks prior to baseline examinations. * history of allergies to oral care/personal care consumer products or their ingredients. * on any prescription medicines that might interfere with the study outcome. * an existing medical condition that prohibits eating and/or drinking for periods up to 4 hours. * history of alcohol and/or drug abuse. * self-reported pregnancy and/or lactating subjects

Keywords: loe and silness gingival index quigley and hein plaque index